NEW TARGET THERAPY FOR TRIPLE NEGATIVE BREAST CANCER

Desarrollado por: Instituto de Investigación Biomédica de Bellvitge (IDIBELL)

Descripción

UNMET NEED:

TNBC constitutes 12% of all breast cancers has a poorer short-term prognosis than other subtypes, has limited treatment options beyond conventional chemotherapy and radiotherapy

PROPOSED SOLUTION:

New chemical entity (NCE) against RANK pathway for the treatment of TNBC

FEATURES:

  • New strategy to inhibit RANK pathway for the treatment of TNBC.
  • RANK is expressed in 40% of TNBC where it was linked with poor clinical outcomes.
  • Cost-effective therapy for TNBC and NSCLC easing the economic burden

Aplicaciones

The most important benefits of this new therapy are based on

1) Medical need to treat TNBC/NSCLC patients

2) The economic burden for public health systems generated by standard non-selected and ineffective cancer treatment.

These new RANK inhibitory molecules will improve the current treatments with less side effects

Estado de protección

RANK is expressed in breast and lung tumors, particularly in tumors from the TNBC and NSCLC subtype, where no targeted therapies are available.
Taking into a count that RANK expression associates with prognosis and RANK receptor can signal in the absence of RANKL, our unique insight to solve this problem is a New strategy to inhibit RANK pathway for the treatment of TNBC and NSCLC.

TRL: Technology concept
IP: Know-how and patent on draft

Cooperación que se desea

Co-development

License agreement

Investment

Responsable: Área de Desarrollo de Negocio e Innovación

Oficina de Transferencia de Tecnología

Contacto (Tel./mail): 93 260 71 06 / Innovacio@idibell.cat

Estado:
En desarrollo, Transferible
Tecnología sanitaria:
Biotecnología y Diagnóstico Molecular (proteómica, genómica, etc...), Medicamentos - Farma